R
Raze Therapeutics
Biotechnology company that engages in the discovery and development of oncology therapeutics
About Raze Therapeutics
Raze Therapeutics was a biotechnology firm established in 2013, focusing on a specific area of cancer research. The company was co-founded by the venture capital firm Atlas Venture, with Peter Barrett of Atlas serving as a co-founder and Chairman of the board. The scientific foundation of Raze was built upon the discoveries of its scientific founders: Vamsi Mootha, M.D., of Massachusetts General Hospital; Joshua Rabinowitz, M.D., Ph.D., of Princeton University; and David Sabatini, M.D., Ph.D., of the Whitehead Institute. These scientists had independently uncovered crucial aspects of one-carbon (1C) metabolism's role in cancer growth. Adam Friedman, M.D., Ph.D., also a co-founder, served as Director of Corporate Development.
The company's central business was the discovery and development of a new class of oncology therapeutics. Raze's strategy revolved around targeting mitochondrial one-carbon (1C) metabolism, a set of pathways essential for the rapid accumulation of biomass required for tumor growth and survival. This approach was considered a new frontier in cancer treatment, as these specific pathways were previously underappreciated and not explicitly targeted for drug development. The company's proprietary drug discovery platform was designed to create therapeutics that could selectively starve cancer cells of the precursors needed for their growth, aiming to treat both solid and hematologic cancers. The business model involved leveraging its platform to build a pipeline of therapeutic candidates, with the potential for future partnerships.
In October 2014, Raze Therapeutics launched publicly with a significant $24 million Series A financing round. The funding was intended to advance the development of its novel therapeutics. Key investors in this round included Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis. Despite its promising start and the notable assembly of scientific and financial backing, the company ultimately ceased operations. It was shut down at the end of 2015, having been in an incubation phase at Atlas Venture. An Atlas partner stated that while the company made intriguing progress, the underlying biology of cancer metabolism proved to be too complex to justify further investment. The company's scientific assets were returned to academia for additional exploration.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2014 | $24M | $96M | Novartis · Atlas Venture · MPM BioImpact · Astellas Venture | — |
| SPINOUT✓Other financing | Jan 2013 | $0 | — | Princeton University · Massachusetts General Hospital · Whitehead Institute | — |
Growth signals
Latest recorded traffic for Raze Therapeutics is 110 monthly website visits. Raze Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Raze Therapeutics in the Cambridge ecosystem
The Raze Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Atlas Venture
Novartis
MPM BioImpact
Astellas Venture- PFPartners Innovation Fund
M Ventures
Other known investors3 additional known investors
Massachusetts General Hospital
Princeton University
Whitehead Institute
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Raze Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Raze Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









